HDP-101-01 (#1382)
Laufzeit: 01.01.2022 - 31.12.2040
imported
Kurzfassung
A Phase1/2a, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
